Ropes & Gray advised MOMA Therapeutics in a collaboration and exclusive license agreement with Bayer to develop and commercialize a small molecule oncology program based on MOMA’s proprietary KNOMATIC platform. The collaboration was announced on October 8.
Under the agreement, Bayer will be responsible for completing further preclinical, development and commercial activities. MOMA will receive an upfront payment and collaboration fee and is eligible to receive near-term discovery, development, and commercial milestones as well as tiered royalties on net sales.
MOMA Therapeutics was represented by life sciences licensing partner Hannah England and life sciences associate Ian Nilsen.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.